180 Life Sciences (ATNF) Competitors $3.74 -0.18 (-4.59%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ATNF vs. TENX, CLDI, AIM, NRXP, MTEX, AWH, KZIA, SLGL, PMCB, and NLSPShould you be buying 180 Life Sciences stock or one of its competitors? The main competitors of 180 Life Sciences include Tenax Therapeutics (TENX), Calidi Biotherapeutics (CLDI), AIM ImmunoTech (AIM), NRx Pharmaceuticals (NRXP), Mannatech (MTEX), Aspira Women's Health (AWH), Kazia Therapeutics (KZIA), Sol-Gel Technologies (SLGL), PharmaCyte Biotech (PMCB), and NLS Pharmaceutics (NLSP). These companies are all part of the "pharmaceutical products" industry. 180 Life Sciences vs. Tenax Therapeutics Calidi Biotherapeutics AIM ImmunoTech NRx Pharmaceuticals Mannatech Aspira Women's Health Kazia Therapeutics Sol-Gel Technologies PharmaCyte Biotech NLS Pharmaceutics Tenax Therapeutics (NASDAQ:TENX) and 180 Life Sciences (NASDAQ:ATNF) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment, community ranking and earnings. Which has higher earnings and valuation, TENX or ATNF? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenax TherapeuticsN/AN/A-$7.71MN/AN/A180 Life SciencesN/AN/A-$19.93MN/AN/A Which has more risk and volatility, TENX or ATNF? Tenax Therapeutics has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Comparatively, 180 Life Sciences has a beta of 0.43, suggesting that its share price is 57% less volatile than the S&P 500. Is TENX or ATNF more profitable? Tenax Therapeutics' return on equity of -123.60% beat 180 Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Tenax TherapeuticsN/A -123.60% -103.37% 180 Life Sciences N/A -523.62%-79.41% Do analysts prefer TENX or ATNF? Tenax Therapeutics presently has a consensus price target of $170.67, suggesting a potential upside of 3,705.28%. Given Tenax Therapeutics' higher probable upside, equities analysts plainly believe Tenax Therapeutics is more favorable than 180 Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenax Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20180 Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Does the media prefer TENX or ATNF? In the previous week, Tenax Therapeutics had 7 more articles in the media than 180 Life Sciences. MarketBeat recorded 9 mentions for Tenax Therapeutics and 2 mentions for 180 Life Sciences. Tenax Therapeutics' average media sentiment score of 0.63 beat 180 Life Sciences' score of 0.00 indicating that Tenax Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenax Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 180 Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of TENX or ATNF? 1.7% of Tenax Therapeutics shares are held by institutional investors. Comparatively, 4.1% of 180 Life Sciences shares are held by institutional investors. 3.7% of Tenax Therapeutics shares are held by insiders. Comparatively, 4.1% of 180 Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer TENX or ATNF? Tenax Therapeutics received 142 more outperform votes than 180 Life Sciences when rated by MarketBeat users. However, 66.67% of users gave 180 Life Sciences an outperform vote while only 56.03% of users gave Tenax Therapeutics an outperform vote. CompanyUnderperformOutperformTenax TherapeuticsOutperform Votes14456.03% Underperform Votes11343.97% 180 Life SciencesOutperform Votes266.67% Underperform Votes133.33% SummaryTenax Therapeutics beats 180 Life Sciences on 9 of the 13 factors compared between the two stocks. Ad Chaikin AnalyticsSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's what that means for your money. Billionaire Wall Street investors are quietly offloading millions of shares. What do they know that you don't? It's arguably the most popular stock in the world. Now, one 50-year Wall Street legend says its day in the sun could finally be coming to an end. Last year, he warned of two stocks that went on to crash 60%.Now he's just issued a warning for the most popular stock in the world: Nvidia (NVDA). Get 180 Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ATNF and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATNF vs. The Competition Export to ExcelMetric180 Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.85M$7.02B$5.40B$8.53BDividend YieldN/A7.96%5.15%4.14%P/E RatioN/A9.36112.5515.07Price / SalesN/A386.151,478.8293.55Price / CashN/A47.3339.8334.04Price / Book-15.585.324.645.01Net Income-$19.93M$153.56M$119.13M$225.46M7 Day Performance-12.21%0.12%0.78%0.37%1 Month Performance165.25%15.23%5.65%3.57%1 Year Performance-55.26%41.16%36.90%29.42% 180 Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATNF180 Life SciencesN/A$3.74-4.6%N/A-54.2%$3.85MN/A0.007Short Interest ↑Gap DownTENXTenax Therapeutics3.1976 of 5 stars$4.49+2.3%$170.67+3,701.0%-69.7%$15.31MN/A0.009News CoverageCLDICalidi Biotherapeutics2.175 of 5 stars$1.35+14.4%$16.67+1,134.6%N/A$15.00M$50,000.000.0041Gap UpHigh Trading VolumeAIMAIM ImmunoTech1.3085 of 5 stars$0.26flat$3.00+1,076.5%-43.7%$14.96M$200,000.00-0.4520Gap UpNRXPNRx Pharmaceuticals1.5874 of 5 stars$1.39+0.7%$31.50+2,174.4%-95.5%$14.89MN/A-0.512MTEXMannatech0.8721 of 5 stars$7.82flatN/A-9.5%$14.74M$122.38M-12.41250Upcoming EarningsAnalyst ForecastNews CoverageAWHAspira Women's Health1.1892 of 5 stars$0.90flat$4.40+388.9%-80.8%$14.45M$9.15M-0.62110Analyst ForecastGap UpKZIAKazia Therapeutics1.6853 of 5 stars$5.57+3.1%$20.00+259.1%+35.7%$14.24M$20,000.000.0012SLGLSol-Gel Technologies2.4605 of 5 stars$0.51+4.1%$5.00+880.2%-60.8%$14.21M$6.56M-0.9450Gap UpPMCBPharmaCyte Biotech0.681 of 5 stars$1.83+1.1%N/A-15.3%$14.05MN/A2.772Gap DownNLSPNLS Pharmaceutics0.2324 of 5 stars$3.60-0.8%N/A+408.8%$13.75MN/A0.006Gap Up Related Companies and Tools Related Companies TENX Competitors CLDI Competitors AIM Competitors NRXP Competitors MTEX Competitors AWH Competitors KZIA Competitors SLGL Competitors PMCB Competitors NLSP Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ATNF) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 180 Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share 180 Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
